NCT05241834

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.

Conditions

• Carcinoma, Non-Small-Cell Lung
• Thyroid Neoplasms

Interventions

Type	Name	Description
DRUG	LOXO-260	Oral

Timeline

• Start date: 2022-03-23
• Primary completion: 2024-09-17
• Completion: 2026-06-01
• First posted: 2022-02-16
• Last updated: 2025-09-04

Locations

16 sites across 2 countries: United States, France

Regulatory

• FDA-regulated drug study